Severe Acute Respiratory News and Research

RSS

First report of a SARS-CoV-2 variant with an ORF7a deletion that dominated an outbreak

In a recent study posted to the medRxiv* preprint server, researchers in Australia determined whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta-ORF7aΔ17del [open reading frame 7a protein with 17-nucleotide (nt) frameshift-inducing deletion] variant has a fitness advantage over the Delta variant lacking the ORF7aΔ17del deletion (Delta-ORF7aintact) and/or the SARS-CoV-2 lineage (A.2.2).

12 Sep 2022

Mucosal vaccination triggers superior T cell response against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* server, researchers in Singapore and the United States demonstrated that intranasal (I.N.) delivery of a mucosal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination triggered a superior T cell response compared to an equivalent dose of antigen delivered by the subcutaneous (S.C.) route.

12 Sep 2022

Research supports use of FFP2/3 masks for HCWs caring for COVID-19 patients

In a recent study posted to the medRxiv* preprint server, researchers in the United Kingdom assessed the aerobiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in United Kingdom (UK) hospitals and the impact of aerosol-generating procedures (AGP).

12 Sep 2022

Vaccines that induce mucosal immunity against SARS-CoV-2 are needed

In a recent study posted to the medRxiv* preprint server, researchers in the United Kingdom studied assessed plasma and nasal antibody (Ab) responses induced after a year of coronavirus disease 2019 (COVID-19)-associated hospitalization and the potential boost by subsequent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in the United Kingdom (UK).

12 Sep 2022

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers in the United States demonstrated the efficacy of a novel biopolymer, N-dihydrogalactochitosan (GC), as an adjuvant for next-generation mucosal coronavirus disease 2019 (COVID-19) vaccine.

12 Sep 2022

Update on SARS-CoV-2 variants detected in animals by USDA

The USDA APHIS has recently updated its web-based dashboard to provide information on all SARS-CoV-2 variants detected in animals

12 Sep 2022

Long-COVID in adults and Ontario's expected burden

Scientists identify the healthcare requirements for adults with long COVID.

12 Sep 2022

What is the risk of SARS-CoV-2 infection among gout patients?

The main outcome of a new study study was to assess the risk of SARS-CoV-2 infection among gout patients.

12 Sep 2022

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

Researchers provided a summary of SARS-CoV-2 infections among children pre- and post-SARS-CoV-2 Delta and Omicron variants of concern (VOCs) emergence.

12 Sep 2022

Small molecule inhibitor found to be effective against SARS-CoV-2 variants

In a new study, researchers developed RK-33, a small molecule inhibitor of DDX3, and evaluated its efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).

12 Sep 2022

BNT162b2 SARS-CoV-2 vaccinations found to reduce incidence of long COVID symptoms

Researchers assessed the association between Pfizer-BioNTech’s SARS-CoV-2 BNT162b2 messenger ribonucleic acid (mRNA) vaccination and the incidence of post-COVID-19 symptoms among Israeli adults.

12 Sep 2022

What is the impact of COVID-19 vaccination on erectile function?

A recent study reported that COVID-19 vaccination does not elevate the risk of erectile dysfunction.

12 Sep 2022

Dissecting vaccinia virus and monkeypox virus-specific T cell responses in humans

In a new study, a team of researchers studied different antigens targeted by vaccinia virus (VACV)- and monkeypox virus (MPXV)-specific T cells.

12 Sep 2022

The long-term clinical status of pediatric patients after testing positive for COVID-19

A recent study found that the most common long COVID symptoms in the pediatric population showed a higher prevalence among patients in the age range of 6-17 years and were identical to those reported in adults.

12 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

In a recent study posted to the bioRxiv* preprint server, researchers in Germany and the United Kingdom investigated the interferon responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant and SARS-CoV-2 Omicron sub-variants BA.1 and BA.5, and their efficacy in protecting cells from influenza A virus super-infection.

12 Sep 2022

Severe Acute Respiratory News and Research

First report of a SARS-CoV-2 variant with an ORF7a deletion that dominated an outbreak

Mucosal vaccination triggers superior T cell response against SARS-CoV-2 variants

Research supports use of FFP2/3 masks for HCWs caring for COVID-19 patients

Vaccines that induce mucosal immunity against SARS-CoV-2 are needed

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

Update on SARS-CoV-2 variants detected in animals by USDA

Long-COVID in adults and Ontario's expected burden

What is the risk of SARS-CoV-2 infection among gout patients?

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

Small molecule inhibitor found to be effective against SARS-CoV-2 variants

BNT162b2 SARS-CoV-2 vaccinations found to reduce incidence of long COVID symptoms

What is the impact of COVID-19 vaccination on erectile function?

Dissecting vaccinia virus and monkeypox virus-specific T cell responses in humans

The long-term clinical status of pediatric patients after testing positive for COVID-19

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

Self-replicating intradermal RNA vaccine against SARS-CoV-2

Brain injury a common consequence of both COVID-19 and influenza

Antibody escape less pronounced with BA.2.75 compared to BA.4/5

Discovery of antibodies that may eliminate the need for COVID vaccines

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News